Compounders Research Compare

CVRx, Inc.(CVRX)

Medical - Devices · Minneapolis, MN

$1.67+0.11 (+6.75%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About CVRx, Inc.

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Minneapolis, MN

223 employees

www.barostim.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Kevin Hykes

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:02:06.029Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:02:06.029Z.

Quote observation: 2026-10-06T16:00:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 44,190,308
Total debt · period ending 2026-06-30: 59,390,000
Cash · period ending 2026-06-30: 64,586,000
TTM operating EBITDA · period ending 2026-06-30: -47,638,000

FMP input reference: e78bbdb3a8988fdd9fdd63a4dcf124b38851ed281a9b1f93071349952e7e00d5

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CVRX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CVRX Competitors' EV/EBITDA Ratio

CVRx, Inc.

Current

Market Cap

$44.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nano-X Imaging Ltd.

Market Cap

$44.27M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Rapid Micro Biosystems, Inc.

Market Cap

$44.31M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DarioHealth Corp.

Market Cap

$44.35M

EV/EBITDA Ratio

N/A

TTM Avg

14.42x

3Y Avg

17.44x

5Y Avg

22.72x

Werewolf Therapeutics, Inc.

Market Cap

$45.20M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioStem Technologies, Inc.

Market Cap

$42.97M

EV/EBITDA Ratio

N/A

TTM Avg

7.89x

3Y Avg

10.87x

5Y Avg

10.87x

Precipio, Inc.

Market Cap

$41.92M

EV/EBITDA Ratio

N/A

TTM Avg

1378.16x

3Y Avg

1378.16x

5Y Avg

1378.16x

Filana Therapeutics, Inc.

Market Cap

$41.16M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Metagenomi, Inc. Common Stock

Market Cap

$40.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Precision Optics Corporation, Inc.

Market Cap

$48.27M

EV/EBITDA Ratio

N/A

TTM Avg

119.16x

3Y Avg

119.16x

5Y Avg

119.16x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
CVRx, Inc. (CVRX)	$44.19M	N/A	N/A	N/A	N/A
Nano-X Imaging Ltd. (NNOX)vs ›	$44.27M	N/A	N/A	N/A	N/A
Rapid Micro Biosystems, Inc. (RPID)vs ›	$44.31M	N/A	N/A	N/A	N/A
DarioHealth Corp. (DRIO)vs ›	$44.35M	N/A	14.42x	17.44x	22.72x
Werewolf Therapeutics, Inc. (HOWL)vs ›	$45.20M	N/A	N/A	N/A	N/A
BioStem Technologies, Inc. (BSEM)vs ›	$42.97M	N/A	7.89x	10.87x	10.87x
Precipio, Inc. (PRPO)vs ›	$41.92M	N/A	1378.16x	1378.16x	1378.16x
Filana Therapeutics, Inc. (FLNA)vs ›	$41.16M	N/A	N/A	N/A	N/A
Metagenomi, Inc. Common Stock (MGX)vs ›	$40.28M	N/A	N/A	N/A	N/A
Precision Optics Corporation, Inc. (POCI)vs ›	$48.27M	N/A	119.16x	119.16x	119.16x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics